B. Michael O'KEefe
B. Michael O'KEefe has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Chloe Y. Wong
Gilead Sciences 333 Lakeside Drive
2 shared publicationsHuy Van Huynh
Gilead Alberta ULC 1021 Hayter Road NW
2 shared publicationsSara A. Bonderoff
Process Development
2 shared publicationsScott A. Wolckenhauer
Gilead Sciences 333 Lakeside Drive
2 shared publications- Alexander F. G. Goldberg
Gilead Sciences 333 Lakeside Drive
1 shared publication Amanda L. Vandehey
Department of Process Chemistry, Gilead Sciences, 333 Lakeside Drive, Foster City, California 94404, United States
1 shared publication
Latest Publications
- 30 September 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (11) , 3123-3137
Synthetic Development and Scale-Up of the Aminoindazole Fragment of Lenacapavir
We describe herein the development and scale-up of the aminoindazole fragment of lenacapavir, a drug recently approved for long-acting treatment of HIV (Sunlenca) and pre-exposure prophylaxis (as Yeztugo and Yeytuo). This five-step route to fragment 1 was developed from the initial “fit-for-purpose” large-scale synthesis to a commercially viable process. Key improvements include an alternative condition to hydroxylamine-O-sulfonic acid-mediated nitrile formation and a significant overhaul of the key Miyaura borylation process. The culmination of all development efforts improved the final product quality and process safety, resulting in a more efficient and higher-yielding process.
- 30 September 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (11) , 3123-3137
Synthetic Development and Scale-Up of the Aminoindazole Fragment of Lenacapavir
We describe herein the development and scale-up of the aminoindazole fragment of lenacapavir, a drug recently approved for long-acting treatment of HIV (Sunlenca) and pre-exposure prophylaxis (as Yeztugo and Yeytuo). This five-step route to fragment 1 was developed from the initial “fit-for-purpose” large-scale synthesis to a commercially viable process. Key improvements include an alternative condition to hydroxylamine-O-sulfonic acid-mediated nitrile formation and a significant overhaul of the key Miyaura borylation process. The culmination of all development efforts improved the final product quality and process safety, resulting in a more efficient and higher-yielding process.
- 15 March 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (4) , 947-955
A Three-Pronged Approach to the Global Debenzylation of an Advanced Furanoside Intermediate en Route to Remdesivir
- 15 March 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (4) , 947-955
A Three-Pronged Approach to the Global Debenzylation of an Advanced Furanoside Intermediate en Route to Remdesivir
- 31 July 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (8) , 3382-3395
Synthesis of Lenacapavir Sodium: Active Pharmaceutical Ingredient Process Development and Scale-up
- 31 July 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (8) , 3382-3395
Synthesis of Lenacapavir Sodium: Active Pharmaceutical Ingredient Process Development and Scale-up
- 19 August 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (17) , 11701-11717
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys
Remdesivir 1 is an phosphoramidate prodrug that releases the monophosphate of nucleoside GS-441524 (2) into lung cells, thereby forming the bioactive triphosphate 2-NTP. 2-NTP, an analog of ATP, inhibits the SARS-CoV-2 RNA-dependent RNA polymerase replication and transcription of viral RNA. Strong clinical results for 1 have prompted interest in oral approaches to generate 2-NTP. Here, we describe the discovery of a 5'-isobutyryl ester prodrug of 2 (GS-5245, Obeldesivir, 3) that has low cellular cytotoxicity and 3-7-fold improved oral delivery of 2 in monkeys. Prodrug 3 is cleaved presystemically to provide high systemic exposures of 2 that overcome its less efficient metabolism to 2-NTP, leading to strong SARS-CoV-2 antiviral efficacy in an African green monkey infection model. Exposure-based SARS-CoV-2 efficacy relationships resulted in an estimated clinical dose of 350-400 mg twice daily. Importantly, all SARS-CoV-2 variants remain susceptible to 2, which supports development of 3 as a promising COVID-19 treatment.
- 19 August 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (17) , 11701-11717
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys
Remdesivir 1 is an phosphoramidate prodrug that releases the monophosphate of nucleoside GS-441524 (2) into lung cells, thereby forming the bioactive triphosphate 2-NTP. 2-NTP, an analog of ATP, inhibits the SARS-CoV-2 RNA-dependent RNA polymerase replication and transcription of viral RNA. Strong clinical results for 1 have prompted interest in oral approaches to generate 2-NTP. Here, we describe the discovery of a 5'-isobutyryl ester prodrug of 2 (GS-5245, Obeldesivir, 3) that has low cellular cytotoxicity and 3-7-fold improved oral delivery of 2 in monkeys. Prodrug 3 is cleaved presystemically to provide high systemic exposures of 2 that overcome its less efficient metabolism to 2-NTP, leading to strong SARS-CoV-2 antiviral efficacy in an African green monkey infection model. Exposure-based SARS-CoV-2 efficacy relationships resulted in an estimated clinical dose of 350-400 mg twice daily. Importantly, all SARS-CoV-2 variants remain susceptible to 2, which supports development of 3 as a promising COVID-19 treatment.
- 19 December 2014
- Published by Wiley in ChemInform
- Vol. 46 (2)
ChemInform Abstract: Palladium-Catalyzed Dearomative Trimethylenemethane Cycloaddition Reactions.
The title reaction proceeds without subsequent rearomatization and can be applied on a broad range of heterocyclic and benzoid substrates.
- 19 December 2014
- Published by Wiley in ChemInform
- Vol. 46 (2)
ChemInform Abstract: Palladium-Catalyzed Dearomative Trimethylenemethane Cycloaddition Reactions.
The title reaction proceeds without subsequent rearomatization and can be applied on a broad range of heterocyclic and benzoid substrates.